Inhibitor | Study Design | ORR | mPFS | References |
Capmatinib | NCT02414139 (GEOMETRY mono-1), N = 364 (phase II), Capmatinib monotherapy | 68.8% | 12.5 mo. | Wolf et al. 2020 [3] |
Tepotinib | NCT02864992 (VISION), N = 152 (phase II), Tepotinib monotherapy | 44.9% | 8.5 mo. | Paik et al. 2020 [4] |